Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases.
BACKGROUND
Dyslipidemia is commonly observed in polycystic ovary syndrome (PCOS) patients. Bezafibrate is a drug for dyslipidemia acting through peroxisome proliferator-activated receptors. We investigated the effects of bezafibrate for ovulation induction in patients with PCOS with dyslipidemia who were resistant to clomiphene citrate (CC).


METHODS
This was a prospective pilot study. Seven infertile, CC-resistant, PCOS patients with dyslipidemia were enrolled in this study. The participants received bezafibrate at 400 mg/day from day 1 of menses and CC at 100 mg/day from day 5 of menses simultaneously until one follicle measuring at least 18 mm in diameter was found by transvaginal ultrasound. The main outcome was ovulation rate.


RESULTS
Five of 7 patients successfully ovulated. The mean number of days of menses until the follicle reached 18 mm in diameter was 16 ± 3 (range 13-20). Monofollicular development was observed in all patients that ovulated. One woman became pregnant and delivered a healthy baby.


CONCLUSIONS
Bezafibrate may be effective for ovulation induction in CC-resistant PCOS patients with dyslipidemia.
Hara
Shuichiro
S
Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Takahashi
Toshifumi
T
Amita
Mitsuyoshi
M
Igarashi
Hideki
H
Kurachi
Hirohisa
H
D000328:Adult; D001629:Bezafibrate / Q000627:therapeutic use*; D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology; D010062:Ovulation Induction / Q000379:methods*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies
D005300:Fertility Agents, Female; D000960:Hypolipidemic Agents; D002996:Clomiphene; D001629:Bezafibrate